Which weight-loss medication is most effective?
Tirzepatide (Zepbound) currently leads clinical efficacy: it targets both the GIP and GLP-1 pathways, producing the largest average weight loss in head-to-head data. Semaglutide (Wegovy), a GLP-1-selective agent, is close behind with a longer track record. Liraglutide (Saxenda) requires a daily injection instead of weekly, and orlistat (Alli/Xenical) is a non-hormonal oral option that blocks about 30% of dietary fat absorption — a very different mechanism with milder but real results.
How do the mechanisms differ?
The table below lays out the four FDA-approved options side by side: receptor targets, route of administration, and the clinical checkpoints your provider will use. The most important pattern: the weekly injectables (Zepbound, Wegovy) dominate efficacy, while the oral (Alli) and daily (Saxenda) options serve specific patient profiles — cost sensitivity, injection aversion, or milder weight-loss goals.
What is the 3-4 month re-evaluation checkpoint?
Every program in Jackson follows the same clinical rule: medications are assessed at 3 to 4 months. If weight loss is on track, treatment continues; if not, the dose adjusts or the medication is switched. This checkpoint is what separates real medical weight management from a prescription-and-pray approach.
The Data Table
| Medication Brand (Generic) | FDA Regulatory Status | Primary Receptor Target | Route of Administration | Biological Action (Brain/Digestive Tract) | Clinical Weight-Loss Efficacy Rating | Mandatory Dosing Timeline Checkpoint | Source |
|---|---|---|---|---|---|---|---|
| Tirzepatide (Zepbound) | FDA-approved for long-term weight management | Dual GIP/GLP-1 receptor agonist | Weekly subcutaneous injection | Slows gastric emptying, suppresses glucagon, and acts centrally on hypothalamic satiety | Rated with the highest clinical weight-loss efficacy of currently available options | Clinicians must re-evaluate patient progress at 3 to 4 months; if the patient has not achieved meaningful weight loss, the provider must adjust the dosage or switch medications | 1, 2, 3, 4, 6, User Description, User Instruction, Source material description and user instructions, Inferred from User Instructions |
| Semaglutide (Wegovy) | FDA-approved | Selective GLP-1 receptor agonist | Weekly subcutaneous injection | Suppresses glucagon, delays gastric emptying, and targets brain satiety centers; highly recommended for patients with concurrent type 2 diabetes and obesity | Highly recommended for patients with concurrent type 2 diabetes and obesity; highly effective | Clinicians must re-evaluate patient progress at 3 to 4 months; if the patient has not achieved meaningful weight loss, the provider must adjust the dosage or switch medications | 1, 2, 3, 4, 5, 6, 13, User Description, User Instruction, Source material description and user instructions, Inferred from User Instructions |
| Liraglutide (Saxenda) | FDA-approved | GLP-1 receptor agonist | Daily subcutaneous injection | Regulates postprandial blood sugar and appetite through intestinal and central mechanisms | Clinically effective weight management option; clinically significant efficacy | Clinicians must re-evaluate patient progress at 3 to 4 months; if the patient has not achieved meaningful weight loss, the provider must adjust the dosage or switch medications | 1, 2, 3, 4, 6, User Description, User Instruction, Source material description and user instructions, Inferred from User Instructions |
| Orlistat (Xenical/Alli) | FDA-approved | Local lipase blocker | Oral capsule | Blocks gastric and pancreatic lipases to prevent the digestion and absorption of up to 30% of dietary fat in the small intestine | Standard therapeutic efficacy for dietary fat absorption inhibition; supports meaningful weight loss; moderate efficacy | Clinicians must re-evaluate patient progress at 3 to 4 months; if the patient has not achieved meaningful weight loss, the provider must adjust the dosage or switch medications | 1, 2, 3, 4, 6, 10, 11, User Description, User Instruction, Source material description and user instructions, Inferred from User Instructions |
Visual Guide
